The evidence that miR-146a and b inhibit IRAK1 and TRAF6 in breast cancer may contradict the hypothesis ofCogswell et al. (2008) that miR-146b relieves inhibition of these molecules in AD, though a functional study of this interaction, as well as the subsequent NF-κB modulation, would be required for clarification. Here, NFKB1 is linked to breast carcinoma.